X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (61) 61
pulmonary hypertension (60) 60
index medicus (49) 49
male (49) 49
middle aged (47) 47
female (46) 46
aged (33) 33
respiratory system (32) 32
adult (30) 30
cardiac & cardiovascular systems (28) 28
hypertension (25) 25
hypertension, pulmonary - physiopathology (25) 25
survival (25) 25
diagnosis (23) 23
hypertension, pulmonary - drug therapy (23) 23
prospective studies (23) 23
arterial-hypertension (22) 22
medicine & public health (19) 19
pulmonary arterial hypertension (16) 16
treatment outcome (16) 16
care and treatment (15) 15
therapy (15) 15
exercise (14) 14
hypertension, pulmonary - diagnosis (14) 14
chronic disease (13) 13
hypertension, pulmonary - mortality (13) 13
prognosis (13) 13
research (13) 13
bosentan (11) 11
guidelines (11) 11
hemodynamics (11) 11
riociguat (11) 11
aged, 80 and over (10) 10
chronic thromboembolic pulmonary hypertension (10) 10
follow-up studies (10) 10
hypertension, pulmonary - etiology (10) 10
risk factors (10) 10
familial primary pulmonary hypertension (9) 9
hypertension, pulmonary - complications (9) 9
mortality (9) 9
patients (9) 9
pneumology/respiratory system (9) 9
retrospective studies (9) 9
antihypertensive agents - administration & dosage (8) 8
cardiology (8) 8
disease (8) 8
health aspects (8) 8
hypertension, pulmonary - therapy (8) 8
iloprost - administration & dosage (8) 8
internal medicine (8) 8
quality of life (8) 8
drug therapy, combination (7) 7
exercise test (7) 7
germany (7) 7
pressure (7) 7
pulmonary arterial-hypertension (7) 7
pulmonary arteries (7) 7
quality-of-life (7) 7
vasodilator agents - administration & dosage (7) 7
cardiovascular (6) 6
drug therapy (6) 6
infusion (6) 6
medicine (6) 6
portopulmonary hypertension (6) 6
pulmonary embolism - complications (6) 6
research article (6) 6
severity of illness index (6) 6
sildenafil (6) 6
vascular resistance (6) 6
adolescent (5) 5
blood pressure (5) 5
capacity (5) 5
chronic heart-failure (5) 5
copd (5) 5
diseases of the respiratory system (5) 5
dysfunction (5) 5
echocardiography (5) 5
epoprostenol (5) 5
exercise tolerance (5) 5
fibrosis (5) 5
further section (5) 5
gastroenterology (5) 5
gastroenterology & hepatology (5) 5
heart-failure (5) 5
hypertension, pulmonary - blood (5) 5
hypertension, pulmonary - diagnostic imaging (5) 5
inhaled iloprost (5) 5
medical research (5) 5
medicine, experimental (5) 5
oncology (5) 5
oxygen consumption (5) 5
peripheral vascular disease (5) 5
pulmonary (5) 5
pulmonary embolism - mortality (5) 5
safety (5) 5
soluble guanylate-cyclase (5) 5
surgery (5) 5
thromboembolism (5) 5
walking (5) 5
6-minute walk distance (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Pulmonary Circulation, ISSN 2045-8932, 5/2018, Volume 8, Issue 2, p. 2045894018769305
In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and... 
soluble guanylate cyclase stimulator | pulmonary arterial hypertension | portal hypertension | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | PULMONARY ARTERIAL-HYPERTENSION | GUIDELINES | EXTENSION | REVEAL | RESPIRATORY SYSTEM | DISEASE | REGISTRY | Hypertension
Journal Article
Circulation, ISSN 0009-7322, 10/2013, Volume 128, Issue 18, pp. 2005 - 2015
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 128, pp. 50 - 56
Abstract Background Riociguat was well tolerated and improved exercise and functional capacity in patients with pulmonary arterial hypertension (PAH) and... 
Pulmonary/Respiratory | Soluble guanylate cyclase stimulator | Riociguat | Pulmonary hypertension | Clinical study | TRIAL | CARDIAC & CARDIOVASCULAR SYSTEMS | RESPIRATORY SYSTEM | PREDICTORS | OPEN-LABEL | HEMOPTYSIS | OUTCOMES | INTERNATIONAL PROSPECTIVE REGISTRY | Enzyme Activators - pharmacology | Antihypertensive Agents - pharmacology | Soluble Guanylyl Cyclase - metabolism | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Enzyme Activators - administration & dosage | Adult | Female | Hypertension, Pulmonary - drug therapy | Walk Test - statistics & numerical data | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Hypertension, Pulmonary - mortality | Pulmonary Embolism - complications | Pyrimidines - administration & dosage | Treatment Outcome | Pyrimidines - pharmacology | Pulmonary Embolism - mortality | Disease-Free Survival | Pyrazoles - administration & dosage | Enzyme Activators - adverse effects | Pyrimidines - adverse effects | Pulmonary Embolism - drug therapy | Aged | Exercise - physiology | Clinical trials | Respiratory agents | Cardiology | Endothelin | Hypertension | Edema | Physical training | Health | Cut-off | Pulmonary arteries | Medical services | Rhinopharyngitis | Fatal | Patients | Survival | Walking | Hemoptysis | Functional anatomy | Functional morphology | Safety | Thromboembolism
Journal Article
Journal Article
BMC PULMONARY MEDICINE, ISSN 1471-2466, 11/2019, Volume 19, Issue 1, pp. 1 - 12
Background Systemic sclerosis (SSc) is a severe rheumatic disease of the interstitial tissue, in which heart and lung involvement can lead to disease-specific... 
SURVIVAL | MORTALITY | Prognosis | SCLERODERMA LUNG | PULMONARY ARTERIAL-HYPERTENSION | 6-MINUTE WALK TEST | CLINICAL CHARACTERISTICS | Cardiopulmonary exercise | Pulmonary hypertension | INTERSTITIAL LUNG-DISEASE | Pulmonary function | RIGHT-HEART CATHETERIZATION | RESPIRATORY SYSTEM | Systemic sclerosis | DELPHI CONSENSUS | MYCOPHENOLATE-MOFETIL
Journal Article
Respiratory Research, ISSN 1465-9921, 10/2013, Volume 14, Issue 1, pp. 104 - 104
Journal Article
European Heart Journal, ISSN 0195-668X, 01/2016, Volume 37, Issue 1, pp. 35 - 44
Journal Article